'Novartis ruling: It is not an anti-patent judgement'

... case about? Novartis applied for a patent for imatinib in the United States in April 1994 and later started marketing a derivative of it, viz., imatinib mesylate as an anti-cancer drug under the brand name of Glivec/Gleevec. Novartis could not apply ...

http://www.rediff.com/business/interview/interview-novartis-ruling-is-not-an-anti-patent-judgement/20130410.htm